NovoCure

About:

An Oncology Company Pioneering a Novel Therapy for Solid Tumors

Website: http://www.novocure.com/

Twitter/X: novocure

Top Investors: Pfizer, Index Ventures, Pfizer Venture Investments, Pharmakon Advisors, JP Morgan Chase

Description:

Novocure™ is dedicated to the development of tumor treating fields therapy (NovoTTF™ Therapy), a new weapon for patients and physicians in the battle against cancer. NovoTTF Therapy is a novel anti-mitotic treatment that has been shown to slow or reverse tumor progression by inducing cell death in certain solid tumors. The company pioneered the concept that the electric properties of cells can be used as an effective target for an anti-neoplastic therapy.

Total Funding Amount:

$1B

Estimated Revenue Range:

$500M to $1B

Headquarters Location:

Jersey, Arkansas, United States

Founded Date:

2000-01-01

Contact Email:

media(AT)novocure.com

Founders:

William F. Doyle, Yoram Palti

Number of Employees:

1001-5000

Last Funding Date:

2024-05-02

IPO Status:

Public

© 2025 bioDAO.ai